{"entity":{"id":"nct06533826","kind":"trial","name":"TRADE DXd","aka":["TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd"],"tldr":"TRADE DXd studies the order of two antibody-linked drugs, trastuzumab deruxtecan and datopotamab deruxtecan. It asks how well one works after the other stops controlling the cancer.","summary":"TRADE DXd studies the order of two antibody-linked drugs, trastuzumab deruxtecan and datopotamab deruxtecan. It asks how well one works after the other stops controlling the cancer.\n\nInterventional study registered as NCT06533826, sponsored by Ana C Garrido-Castro, MD. Registry phase: 2. Registry enrollment is 357 participants (estimated). Registry status checked October 10, 2026: recruiting. UCSF lists this study as open to eligible people; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"recruiting","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT06533826","url":"https://clinicaltrials.gov/study/NCT06533826"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT06533826"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["datopotamab-deruxtecan","trastuzumab-deruxtecan"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06533826","phase":"2","setting":"HER2-negative metastatic breast cancer, including HER2-low disease","sponsor":"Ana C Garrido-Castro, MD","participation":[{"nct":"NCT06533826","source":"https://clinicaltrials.gov/study/NCT06533826","fetchedAt":"2026-10-10T20:54:19.150632Z","studySha256":"eb6773c39dc4a205db47ad372a89196720f1b2065eb4d6015e75c271b3663198","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-26","leadSponsor":"Ana C Garrido-Castro, MD","collaboratorCount":2,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":357,"enrolmentType":"ESTIMATED","siteCount":11,"recruitingSiteCount":10,"countries":["United States"]}],"started":"2024-10-29","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06533826/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}